Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Dec;61(12):1090–1094. doi: 10.1136/ard.61.12.1090

Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype

I Peene 1, L Meheus 1, E Veys 1, F De Keyser 1
PMCID: PMC1753972  PMID: 12429541

Abstract

Objective: To determine the diagnostic distribution in a consecutive anti-SSA and/or anti-SSB positive population.

Methods: A total of 15 937 serum samples from 10 550 consecutive patients were analysed for antinuclear antibodies (ANAs) on HEp-2 cells. Serum samples positive for ANAs were analysed by immunodiffusion and line immunoassay with recombinant SSA-Ro52, natural SSA-Ro60, and recombinant SSB.

Results: Among ANA positive patients in whom clinical information was available, 181 consecutive patients with anti-SSA and/or anti-SSB antibodies were identified, Disease associations were systemic lupus erythematosus (SLE) (45.3%), primary Sjögren's syndrome (pSS) (14.4%), scleroderma (8.8%), RA (7.7%), cutaneous lupus (7.7%), and dermatomyositis (2.2%). The ratio of diagnoses differed according to the anti-SSA/anti-SSB serotype. Scleroderma and dermatomyositis were enriched among mono-Ro52 reactive serum samples (34.2% and 10.5% respectively). Single reactivity towards Ro60 or anti-Ro60 with anti-Ro52 predisposed for SLE (80.0% and 52.2% respectively). Triple reactivity towards Ro52, Ro60, and SSB was primarily linked with SLE (55.8%) followed by pSS (20.9%). Anti-SSA on immunodiffusion increased the chance for SLE (62.8%), whereas isolated anti-SSB reactivity on immunodiffusion was less indicative for SLE (14.3%) and predisposed more for cutaneous lupus (23.8%) and pSS (33.3%).

Conclusion: The diagnostic range associated with anti-SSA or anti-SSB reactivity differs significantly according to the detailed serotype defined by line immunoassay and immunodiffusion.

Full Text

The Full Text of this article is available as a PDF (166.8 KB).

Figure 1 .

Figure 1

Open in a new tab

Different combinations of reactivities towards Ro52, Ro60, and SSB defined by line immunoassay. Lane a: anti-Ro52 antibodies; lane b: anti-Ro60 antibodies; lane c: anti-SSB antibodies; lane d: anti-Ro52 and anti-Ro60 antibodies; lane e: anti-Ro60 and anti-SSB antibodies; lane f: anti-Ro52 and anti-SSB antibodies; lane g: anti-Ro52 and anti-Ro60 and anti-SSB antibodies.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Ben-Chetrit E. The molecular basis of the SSA/Ro antigens and the clinical significance of their autoantibodies. Br J Rheumatol. 1993 May;32(5):396–402. doi: 10.1093/rheumatology/32.5.396. [DOI] [PubMed] [Google Scholar]
  3. Boire G., Gendron M., Monast N., Bastin B., Ménard H. A. Purification of antigenically intact Ro ribonucleoproteins; biochemical and immunological evidence that the 52-kD protein is not a Ro protein. Clin Exp Immunol. 1995 Jun;100(3):489–498. doi: 10.1111/j.1365-2249.1995.tb03728.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brouwer R., Hengstman G. J., Vree Egberts W., Ehrfeld H., Bozic B., Ghirardello A., Grøndal G., Hietarinta M., Isenberg D., Kalden J. R. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001 Feb;60(2):116–123. doi: 10.1136/ard.60.2.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brucato A., Buyon J. P., Horsfall A. C., Lee L. A., Reichlin M. Fourth international workshop on neonatal lupus syndromes and the Ro/SSA-La/SSB System. Clin Exp Rheumatol. 1999 Jan-Feb;17(1):130–136. [PubMed] [Google Scholar]
  6. Cavazzana I., Franceschini F., Belfiore N., Quinzanini M., Caporali R., Calzavara-Pinton P., Bettoni L., Brucato A., Cattaneo R., Montecucco C. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheumatol. 2001 Jul-Aug;19(4):403–409. [PubMed] [Google Scholar]
  7. Emlen W., O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 1997 Sep;40(9):1612–1618. doi: 10.1002/art.1780400910. [DOI] [PubMed] [Google Scholar]
  8. Frank M. B., McCubbin V., Trieu E., Wu Y., Isenberg D. A., Targoff I. N. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun. 1999 Mar;12(2):137–142. doi: 10.1006/jaut.1998.0265. [DOI] [PubMed] [Google Scholar]
  9. Kelekar A., Saitta M. R., Keene J. D. Molecular composition of Ro small ribonucleoprotein complexes in human cells. Intracellular localization of the 60- and 52-kD proteins. J Clin Invest. 1994 Apr;93(4):1637–1644. doi: 10.1172/JCI117145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. López-Longo F. J., Rodríguez-Mahou M., Escalona M., Pérez T., Monteagudo I., Sánchez-Atrio A., Grau R., González C., Moreno A. C., Carreño L. Heterogeneity of the anti-Ro(SSA) response in rheumatic diseases. J Rheumatol. 1994 Aug;21(8):1450–1456. [PubMed] [Google Scholar]
  11. McCauliffe D. P., Wang L., Satoh M., Reeves W. H., Small D. Recombinant 52 kDa Ro(SSA) ELISA detects autoantibodies in Sjögren's syndrome sera that go undetected by conventional serologic assays. J Rheumatol. 1997 May;24(5):860–866. [PubMed] [Google Scholar]
  12. Meheus L., van Venrooij W. J., Wiik A., Charles P. J., Tzioufas A. G., Meyer O., Steiner G., Gianola D., Bombardieri S., Union A. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol. 1999 Mar-Apr;17(2):205–214. [PubMed] [Google Scholar]
  13. Peene I., Meheus L., Veys E. M., De Keyser F. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis. 2001 Dec;60(12):1131–1136. doi: 10.1136/ard.60.12.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. doi: 10.1002/art.1780230510. [DOI] [PubMed] [Google Scholar]
  15. Rutjes S. A., Vree Egberts W. T., Jongen P., Van Den Hoogen F., Pruijn G. J., Van Venrooij W. J. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol. 1997 Jul;109(1):32–40. doi: 10.1046/j.1365-2249.1997.4081308.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Scofield R. H., Farris A. D., Horsfall A. C., Harley J. B. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Arthritis Rheum. 1999 Feb;42(2):199–209. doi: 10.1002/1529-0131(199902)42:2<199::AID-ANR1>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  17. Slater C. A., Davis R. B., Shmerling R. H. Antinuclear antibody testing. A study of clinical utility. Arch Intern Med. 1996 Jul 8;156(13):1421–1425. [PubMed] [Google Scholar]
  18. Slobbe R. L., Pruijn G. J., Damen W. G., van der Kemp J. W., van Venrooij W. J. Detection and occurrence of the 60- and 52-kD Ro (SS-A) antigens and of autoantibodies against these proteins. Clin Exp Immunol. 1991 Oct;86(1):99–105. doi: 10.1111/j.1365-2249.1991.tb05780.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  20. Tan E. M., Smolen J. S., McDougal J. S., Butcher B. T., Conn D., Dawkins R., Fritzler M. J., Gordon T., Hardin J. A., Kalden J. R. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum. 1999 Mar;42(3):455–464. doi: 10.1002/1529-0131(199904)42:3<455::AID-ANR10>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  21. Targoff I. N., Miller F. W., Medsger T. A., Jr, Oddis C. V. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997 Nov;9(6):527–535. doi: 10.1097/00002281-199711000-00008. [DOI] [PubMed] [Google Scholar]
  22. Vitali C., Bombardieri S., Moutsopoulos H. M., Balestrieri G., Bencivelli W., Bernstein R. M., Bjerrum K. B., Braga S., Coll J., de Vita S. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993 Mar;36(3):340–347. doi: 10.1002/art.1780360309. [DOI] [PubMed] [Google Scholar]
  23. Zimmermann C., Smolen J. S., Graninger W., Petera P., Fabini G., Hassfeld W., Höfler E., Steiner G. Fine specificity of anti-Ro(SSA) autoantibodies and clinical manifestations in patients with systemic lupus erythematosus. J Rheumatol. 1996 Nov;23(11):1897–1903. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES